Pearl Steinzor

Study highlights barriers to care, treatment preferences, and interest in research participation in psoriasis in the Latine community.

Self-efficacy–based sexual counseling may improve sexual function among breast cancer survivors, study finds.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, continues his discussion on treatment approaches for patients with cardiovascular-kidney-metabolic (CKM) syndrome.

How does age, sex, comorbidity, and screening history influence the cost-effectiveness of continuing colorectal cancer (CRC) screening in older adults?

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.

The European Society for Medical Oncology (ESMO) Congress featured findings on overall survival, disparities, and artificial intelligence in cancer research.

The most-read psoriasis content in 2024 covered efficacy and safety findings of various drug clinical trials.

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the interconnected condition of cardiovascular-kidney-metabolic (CKM) syndrome, which includes obesity, diabetes, chronic kidney disease, and cardiovascular disease.

Understanding postural orthostatic tachycardia syndrome is important in order to improve prevention and outcomes.

Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic lymphocytic leukemia (CLL).

Study identifies underutilization of testing, with disparities by race and sex.

Both candidates combine 2 already licensed vaccines to prevent influenza and COVID-19.

The Community Oncology Alliance (COA) meetings featured expert discussions around the evolving landscape of oncology care and health care reform.

Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program, member of the Lymphoma Research Foundation’s Scientific Advisory Board, shares findings on innovative strategies to improve access to new therapies in pediatric cancer.

At an Institute for Value-Based Medicine® event held in Aurora, Colorado, experts discussed strategies to improve patient outcomes and manage health care costs in neurological diseases.

Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients with multiple myeloma.

Novel strategies in the VISIBLE trial set a new standard for recruiting and retaining diverse participants with skin of color in dermatology clinical trials.

Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey, shares long-term follow-up data on the efficacy and safety of linvoseltamab in patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center, examines disparities in lymphoma outcomes using retrospective data from cooperative groups over 15 years.

Study finds no benefit of fluvoxamine in shortening COVID-19 symptom duration among mild to moderate cases.

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory syncytial virus (RSV).

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, highlights key topics and takeaways that attendees can expect from this year's meeting.

Metformin and lifestyle changes show no significant impact on atrial fibrillation (AFib) burden or progression compared with standard care.